IMRN

0.89985.86%
GS

Glenn S. Tillotson

Member of Advisory Board

Dr. Glenn S. Tillotson, Ph.D., FIDSA, FRSM, FCCP, FISC serves as a Member of Advisory Board at Immuron Limited. He served as Senior Vice President of Medical Affairs at Cempra, Inc. since July 28, 2016 until December 15, 2016. Dr. Tillotson served as Senior Scientific Advisor of Optimer Pharmaceuticals Inc. and served as its Senior Vice President of Medical Affairs since February 2011. Dr. Tillotson served as the Head of Medical Affairs of ViroPharma Inc. since joining it in October 2008 and was responsible to lead its medical affairs team providing medical leadership to disease-specific strategy to support optimal positioning of marketed and development products. Prior to joining ViroPharma, Dr. Tillotson served as Executive Director of Scientific Affairs at Replidyne. Dr. Tillotson served as Vice President of Scientific and Medical Relations of Oscient Pharmaceuticals Corp. from April 2004 to 2006 and served as its Head of Factive. Dr. Tillotson has many years pharmaceutical experience in preclinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr. Tillotson is a well-known leader in the anti-infectives arena with many years at Bayer AG, where he played a key role in establishing Bayer AG anti-infective global franchise. Dr. Tillotson led the Medical Education and Opinion Leader Development of leading physicians worldwide in support of various product launches, including moxifloxacin (Avelox(R)). He served as a Scientific Advisors of Spero Therapeutics, LLC since May 2014. Dr. Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents during his tenure at Bayer, ViroPharma, Optimer and other pharmaceutical firms. Dr. Tillotson has held several key committee positions with the American College of Chest Physicians. Dr. Tillotson is on the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering. Dr. Tillotson has published over 100 peer-reviewed manuscripts, presented more than 250 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Diseases. He is a Fellow of the Royal Society of Medicine and a Fellow of the College of Clinical Pharmacists. He holds a Bachelors of Science in Microbiology and Biochemistry from Liverpool Polytechnic, a Master of Science in Medicine from University of Manchester Medical School and Ph.D. from Richmond University in London, UK. He obtained training in Medical Microbiology and Infectious Diseases in the United Kingdom.

Positions